Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04907968 · ClinicalTrials.gov registry record · Phase 1
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
A Phase 1 study, sponsored by Mersana Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04907968 is a Phase 1 study that was terminated before completion, run by Mersana Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT04907968, a Phase 1 study, was terminated before completion, sponsored by Mersana Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). The trial consists of dose escalation (DES) and expansion (EXP) portion. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity.
Interventions
- DRUG Carboplatin
- DRUG XMT-1536 (Upifitamab Rilsodotin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04907968
The ClinicalTrials.gov registry entry for NCT04907968 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT04907968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04907968 about?
NCT04907968 is a clinical study titled "Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer". Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cance...
What is the current status of trial NCT04907968?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-06-11. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT04907968?
The interventions under investigation include: Carboplatin (DRUG), XMT-1536 (Upifitamab Rilsodotin) (DRUG).
Who is sponsoring clinical trial NCT04907968?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.